Handbook 2015

2015 Handbook genesis 2015 60 years ago, British researchers co-discovered the structure of DNA. Today they continue to make world-changing discoveries. Unlock your global business potential with UK innovation.

DNA (deoxyribonucleic acid) molecule gov.uk/ukti sponsors 3

Genesis 2015 Sponsors Contents Gold Sponsors Welcome 6

Keynote Speakers 7

Speaker Profiles 8 - 25

Programme 26 - 27

Floor Plan and Exhibitor List 28 - 29

The Source Lounge 32

Exhibitors 34 - 43

Silver Sponsors Corporate Patron

Corporate Sponsors

Bronze Sponsors Partners

Supporters 60 years ago, British researchers co-discovered the structure of DNA. Today they continue to make world-changing discoveries. Unlock your global business potential with UK innovation. Media Partners DNA (deoxyribonucleic acid) molecule gov.uk/ukti

Media Supporters Catalysing the power “Life sciences is the most of the golden triangle exciting and rewarding sector to invest in” Dr Eliot Forster, CEO, Immunocore, and Executive Chair, MedCity

From the Francis Crick Institute and the Early-stage life sciences companies offer Cell Therapy Catapult to Imperial West and exciting opportunities for investors to make AstraZeneca’s Global R&D Centre, the life excellent returns and make a difference to sciences constellation of the London-Oxford- the health and well-being of thousands. Cambridge golden triangle is in a period of unprecedented ambition. Angels in MedCity runs regular free workshops for potential investors to understand the sector, Established by the Mayor of London with the identify strong propositions and connect with capital’s three academic health science centres, angel syndicates led by sector experts. MedCity is championing entrepreneurship and investment to build on the region’s global Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. reputation as a world-leading life sciences cluster.

Find out how we can help you do business Find out more about opportunities for across the greater south east of England investors and emerging companies at medcityhq.com angelsinmedcity.org.uk

MedCity_Adverts_Genesis_Conference_2015_AW.indd All Pages 05/11/2015 14:29 Catalysing the power “Life sciences is the most of the golden triangle exciting and rewarding sector to invest in” Dr Eliot Forster, CEO, Immunocore, and Executive Chair, MedCity

Find out how we can help you do business Find out more about opportunities for across the greater south east of England investors and emerging companies at medcityhq.com angelsinmedcity.org.uk

MedCity_Adverts_Genesis_Conference_2015_AW.indd All Pages 05/11/2015 14:29 6 welcome

welcome Dear Genesis Participant,

Welcome to our 15th Annual Genesis Conference

The overarching theme of this year’s informatics elements of the sector. We conference is ‘Taking Bio-Innovation continue to have our partnering system to a Global Market’. Our programme for you and are delighted that the Life addresses this with content covering the Sciences Hub Wales is our new partner three main pillars for growth in the sector; for this. You can find partnering in the technology, finance and people. Fleming Room. The One Nucleus team and I know you Last year we brought you the first will make full use of the presentations, ever ‘Genesis Fringe’ – a range of great debate, networking and the exhibition events and activities taking place before hall to catch up with old friends and make and after Genesis that One Nucleus is some new ones, update yourselves on delighted to support and promote. We trends in the sector and create and scope got such great feedback from Genesis out new business opportunities. Please guests, who were able to maximise do not hesitate to talk with any one of the benefits of their trip, that we have the One Nucleus team. We are here to brought it back for 2015. I hope you have help you make the most of your time at experienced, or plan to experience a Genesis and ensure you leave us with Genesis Fringe event during your time in a spring in your step and light of heart London. Do check out page 29 for details. knowing that you have just had a hugely productive day! We are also continuing with the much appreciated (by us and guests) The One Nucleus membership continues collaboration with the SCRIP team on to grow and we remain the largest Genesis. We have worked incredibly membership organisation for the sector closely together on key elements of in Europe (by some distance, with over the day, evolving it to enhance the 470 organisations as members). The knowledge-sharing opportunities for majority of our members are based in you. The insights gained over the day Cambridge and London with many of will fuel the much anticipated SCRIP-One them here today. Nucleus Plenary Debate providing the panellists and delegates with the chance Genesis continues to be a truly to share their suggestions to enhance international networking exhibition that success at individual, company and sector we intentionally evolve year on year. wide level. New for 2015 we have an intentionally reformatted Exhibition Hall affording all Finally and very importantly I would stands greater visibility, more specific like to extend a big ‘thank you’ to all our Source Hubs (after the success of our Sponsors, supporters and collaborators inaugural Source Lounge last year) and for helping to make Genesis happen. 1-2-1 clinic options on (i) Get Ready for JP Morgan 2016 (ii) Outsourcing R&D I wish everyone an excellent event and and (iii) Preparing for Start-Up and High thank you for taking part. Growth. We have updated the core programme to include an additional Plenary Panel which increases the programme content and dynamic further as does the addition of the Farr Institute stream which brings in the health keynote speakers 7

George Freeman MP Minister for Life Sciences

George was elected to Parliament in 2010 after a 15 year career across the life sciences sector, in particular working with hospitals, clinical researchers, patient groups, and biomedical research companies to pioneer novel healthcare innovations.

Following his election to Parliament in 2010, George served as PPS to the Minister of State for Climate Change. He was appointed Government Adviser on Life Sciences in July 2011, working closely with the Department of Health and coordinating the Government’s Life Science and Innovation, Health and Wealth Strategies (2011), and the Agri-Tech Industrial Strategy (2013). Following that, he was appointed to the post of Prime Minister’s UK Trade Envoy.

On July 15 2014, George was appointed as Minister for Life Sciences, a Parliamentary Under-Secretary of State at the Department of Health and Department of Business, Innovation and Skills. His mission is to make the UK the best place in the world to discover and develop 21st Century healthcare innovations.

Richard Mason Head of Johnson & Johnson Innovation, London

Richard joins Johnson & Johnson Innovation from XO1-Limited where he served as CEO before it was acquired by Janssen earlier this year. Richard is a physician by training and has had a number of senior roles in innovative biotechnology companies. Richard specializes in transforming companies through collaborations and deal-making, including multiple acquisitions. Richard earned his MBA from The Judge Business School University of Cambridge.

Mike Ward Chief Content Officer, SCRIP Intelligence and Datamonitor

Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year. 8 speaker profiles

Eva-Lotta Allan CBO and Board Director, Immunocore

Eva-Lotta Allan has over two decades of business development experience from the biotechnology and life science industry of private and public companies. She joined Immunocore as Chief Business Officer and Board Director in May 2013. Since then Immunocore has established four pharmaceutical discovery partnerships.

Eva-Lotta was previously at Ablynx, serving as CBO for almost seven years and held roles in biotech companies including Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals.

Davidson Ateh CEO, BioMoti

Davidson Ateh is a health entrepreneur. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship and has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti candidates have the potential to be ground-breaking cancer therapies for patients in need.

Graham Ball Professor of Bioinformatics, Nottingham Trent University and CSO of CompanDX and CompanDX(Wuhan)

Prof Graham Ball is Professor of Bioinformatics at Nottingham Trent University and CSO of CompanDX Ltd and CompanDX(Wuhan) Ltd. He is Associate Director the John Van Geest Cancer Research Centre and biostatistics lead on three clinical projects. He has been involved in the development and validation of biomarker discovery algorithms using Artificial Neural Networks for the last 20 years. After a PhD (UN funded) and a Post Doc modelling pollution and plant environmental interactions with ANNs at NTU, in 2000 he shifted the focus of his analysis to proteomic and genomic data searching for proteins and genes associated with cancer and infectious diseases. His current research interests are directed at the classification and characterisation of biological systems including diagnostic and classification modelling of microbial pathogens, cancer clinical pathology, allergic responses and viral diseases through the use of ANNs and other machine learning techniques.

Laurence Barker Head of Investment Management, GSK

Laurence is Head of Investment Management in the Worldwide Business Development team at GSK. Laurence is responsible for managing GSK’s venture investment portfolio and relationships with key partners including Index Ventures, and SV Life Sciences with regard to the recently launched Dementia Discovery Fund. In addition, he leads licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at biotech companies Syntaxin and MorphoSys. Laurence holds an MBA from Cambridge and a PhD in Biochemistry from the University of Tuebingen. speaker profiles 9

Michael Barnes Director of Bioinformatics, William Harvey Research Institute and Co-Investigator, MRC Farr London, Queen Mary University of London

Michael Barnes holds a Biology BSc and PhD. in Molecular Genetics from Cardiff University. In 1997 he joined the new Bioinformatics team at SmithKline Beecham (later GSK), to mine the outputs of the nascent human genome project. At GlaxoSmithKline he led a computational biology team focused on the application of genetic, genomic and chemogenomic approaches to drug discovery and patient stratification. A strong advocate of pre-competitive collaboration among pharma and closer collaboration with academia, Michael co-led an EFPIA team to gain EU-IMI funding for the OpenPhacts IMI project (www.openphacts.org), which constructed an open tool box of chemo- and bioinformatics tools. After fourteen years at GSK, he co-founded Open Innovation Pharma Partners, with Prof Jackie Hunter, CBE. Michael joined the William Harvey Research Institute in 2012 as Director of Bioinformatics. Michael is a co-investigator at the MRC Farr London. His team are working across diverse domains, including genomics, drug discovery, stratified medicine and health informatics with a unified objective to drive forward translation into the clinic.

Michael serves on several project and advisory boards, including the MRC-eMedLab HPC facility, the IMI etriks project, IMI OpenPHACTS and the F1000 faculty (Bioinformatics). He has published widely and also edited the successful John Wiley Book, Bioinformatics for Geneticists. He holds a visiting Senior Lecturer post at the Institute of Psychiatry, Kings College London.

Steve Bates CEO, Bioindustry Association (BIA)

Since his appointment as Chief Executive of the Bioindustry Association in 2012, Steve Bates has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors.

Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society’s Science, Industry & Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations.

An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. 10 speaker profiles

Morris Berrie Co-Chairman, TTS Global Initiative

Dr. Morris S. Berrie is Co-Founder/Chairman of the TTS Global Initiative and a Director of Tech Investor. TTS is an organization that globally facilitates business understanding and consequently deal flow in the early stage start-up / SME biotech sector. TTS is currently involved in two EU Horizon 2020 projects. Tech Investor specifically consults for and advises companies on business development, strategy, licensing and capital raising.

Previously Dr Berrie was both the CEO and Editor-in-Chief of the Biotechnology Investment Group; Head of Global Intelligence and Business Development for Nature Publishing Group; Director of the Investigational Drug database (IDdb) at Current Drugs (now Thomson Reuters Pharma) and has worked at Schering AG and GlaxoWellcome. He is a Chartered Chemist (CChem), a Member of the Royal Society of Chemistry (MRSC) and was the recipient of a European DG Post-Doctoral Fellowship upon completing his Ph.D. at Imperial College, London. He is currently a Director of two Biotech start-ups, and additionally sits on the editorial board, business strategy and publishing committees of the Royal Society of Chemical Industry (Wiley).

Kate Bingham Managing Partner, SV Life Sciences

Kate Bingham joined SVLS in 1991.

Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Affinium, Alantos, Auxilium, Convergence, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, MedNova, Micromet, Oncoethix, PowderMed, RespiVert and Vantia and current investments including Atopix, Autifony, Bicycle, Calchan, Kalvista, Karus, Kesios, Pulmocide, TopiVert and VHSquared.

Kate has played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee as well as the Investment Committees for al SV’s funds.

Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).

Aisling Burnand MBE CEO, AMRC

Aisling’s role at AMRC is to champion the voice of the medical research sector, influencing the policy and research environment by harnessing the collective strengths of AMRC’s 139 members. Key to this is demonstrating the huge impact research charities have on health and wellbeing. Placing the voice of patients at the heart of medical research is vital in order to bring about change. Driven by a passion to make a difference, she took up the AMRC CEO role in Sept 2014. speaker profiles 11

John Burt CEO, Abzena

John has been CEO of PolyTherics since May 2011, having joined as Chief Business Officer in November 2011. In this time, the company has secured a licence agreement with Nuron Biotech for the development of TheraPEG interferon β, closed a £2.75 million funding round, expanded the application of the company’s technologies into the antibody-drug conjugate field and broadened the offering through the acquisition of Warwick Effect Polymers.

Prior to joining PolyTherics he co-founded Thiakis, with Professor Steve Bloom (Imperial College), which he led as CEO through a major financing round in 2006 and ultimately to its sale to Wyeth in 2008. John previously led medical and life sciences technology transfer for Imperial Innovations, responsible for a range of licensing transactions and was involved with a number of spin-out companies including as a board director of Sterix through the acquisition by Ipsen.

His career started as a management consultant with Coopers & Lybrand before entering the pharmaceutical industry with Vanguard Medica and then moving to GSK for a variety of technology licensing, predictive medicine strategy and corporate development roles.

John holds an M.A. (Natural Sciences) from University of Cambridge and a D.Phil (molecular biology) from University of Oxford.

Mark Carlton President and CSO, Takeda Cambridge

Mark is President and CSO of Takeda Cambridge (TCB), Takeda’s discovery research operation in the UK. TCB focusses primarily on CNS diseases but also covers CV/Renal and some GI related areas. TCB arose from Takeda’s acquisition in 2007 of Paradigm Therapeutics, a biotech spun out of the University of Cambridge by Mark in 2001. Mark gained his PhD in Genetics from Cambridge, under Prof. Sir Martin Evans, where he also continued his academic studies.

Sue Charles Managing Partner, Instinctif Partners

Sue has been providing communications counsel in the biotech sector for some three decades, supporting companies at the interface of innovation and wealth creation. She specialises in supporting clients operating across International borders, with significant experience in game- changing technologies. An entrepreneur and business leader, she has founded and led three consultancies, executing on investment and M&A transactions, as well as biotech CEO, non- executive and trustee experience. She holds a First class degree in Biochemistry from Oxford and an MBA from Cranfield Business School. SAVE THE DATE

THURSDAY 9 JUNE 2016 WWW.MEDISCIENCE-EVENT.CO.UK

THE BREWERY, LONDON EC1

www.mediscience-event.co.uk The European Mediscience event is integral to the progress of Europe’s Life Science sector and you can be part of this prestigious event in the following ways: o Host a table of ten at the event (subject to availability) o Advertise in the brochure that is distributed to all 500 attendees o Sponsor an award or the menu (subject to availability) o Nominate a client or company (self nominations are also welcome) o Participate in the marketing and PR campaign

@EuroMed_Awards #MediscienceAwards Search: European Mediscience Awards 7 MARCH 2016 NOMINATIONS OPEN Some of our sponsors and associates: 15 APRIL 2016 NOMINATIONS CLOSE 5 MAY 2016 THE VOTING PANEL MEETS 6 MAY 2016 SHORTLIST ANNOUNCED 9 JUNE 2016 AWARDS DINNER AT THE BREWERY, LONDON EC1 speaker profiles 13

Renata Crome Project Leader, Cancer Research UK

Renata started her career in academic research at St Thomas’s Hospital, London working on cardiovascular metabolism, cardiac arrhythmias and heart transplants .

She joined the Dept. of Cardiovascular Pharmacology at Roche gaining >25 years extensive experience in the scientific and clinical development, regulatory approval and commercialisation of new medicines.

Renata has spent the majority of her pharmaceutical career in early development, as Clinical Pharmacologist in the CVS, Infectious Diseases, and CNS therapeutic areas , then leading the Clinical Pharmacology Operations group, responsible for delivery of all the Roche Clinical Pharmacology Programmes.

As a Project Leader, she led project teams across a broad spectrum of therapeutic areas at all stages of development from the early discovery phase to life-cycle management for Roche’s key projects including Tamiflu the influenza drug , Avastin and Obinutuzumab Oncology molecules . Renata’s most recent role was global head of Early Development Clinical Operations and Deputy Head of Early Development at Roche.

She moved to join Cancer Research UK in early 2015 , to contribute her extensive knowledge of drug and particularly Oncology drug development to support the CRUK drug development programmes and heads up the study , project and portfolio management group.

Astrid Maria Dahl Executive Business Development Director - Oncology, AstraZeneca

Astrid Maria Dahl is Executive Business Development Director, Scientific Partnering & Alliances – Oncology at AstraZeneca, a global pharmaceutical company operating in more than 100 countries worldwide. In this role she is responsible for global licensing and partnering with regards to oncology assets in early clinical development and research. Maria has a dual technical and business background and more than ten years’ experience in the US and UK biotechnology and pharmaceutical industry, primarily in the areas of business development and portfolio management.

Following a Ph.D. in Tumor Immunology from the Imperial Cancer Research Fund/University College London in the United Kingdom, she did her post-doctoral work in immunology at Harvard Medical School in Boston, USA. She then obtained an MBA from the University of California at Berkeley and moved into industry. She initially worked in the business development team at the San Francisco based biotechnology company Cell Genesys prior to moving to London to work for IPSEN from 2004 to 2012. At IPSEN she was responsible for oncology in the corporate business development team prior to being promoted in 2008 to Vice-President to head the entire oncology portfolio management team. She joined AstraZeneca’s business development team in early 2012 and is based in the offices in Cambridge, UK.

Jane Dancer CBO, F-star

Jane Dancer is Chief Business Officer at F-star having joined the company in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge. 14 speaker profiles

Chris Farmakis EC Fund Manager, GLE Group

Chris is working for GLE Group, an economic intervention organisation headquartered in London with nationwide coverage in the UK and operational branches in Prague and Brussels. His role is provide support for capital functions (funding and private finance) under Enterprise Europe Network for London. He has overseen over £60m worth of private capital transactions in the form of equity investments in SMEs and more than £250m worth of debt structuring. Since 2008 more than £25m worth of grant funding (FP7, TSB, NESTA, Welcome) has been awarded to London SMEs through EEN support.

Kieron Flanagan Senior Lecturer in Science and Technology Policy, Manchester Institute of Innovation Research

Kieron is Senior Lecturer in Science and Technology Policy at the University of Manchester’s Manchester Institute of Innovation Research. He has worked in the area of science policy for more than 15 years, focusing on funding policy, research infrastructure, research performing organisations and the internationalisation of science. He has worked extensively with and for policy-makers in the UK and beyond. He blogs about science policy for The Guardian’s “Political Science” blog and tweets as @kieronflanagan.

Sally Ann Forsyth CEO, Norwich Research Park

Sally Ann’s role is to create a supportive environment for innovation and develop Norwich Research Park as a world class science park.

Previously Sally Ann was Director of Science Parks for Goodman International responsible for development of Harwell Oxford and Colworth Science Park. A former Principal with Unilever Ventures, Sally Ann focused on technology spin outs.

Sally Ann holds a PhD in molecular biology from the University of Cambridge and is a qualified management accountant.

Flic Gabbay Founder and Partner, TranScrip

Flic is Managing Partner of TranScrip of which she was a co-founder in 2008 and has worked in the pharmaceutical industry for more than 30 years. She has held senior positions in pharma and biotech companies in Europe and North America and worked on a range of products including small molecules and biologicals. She has been involved in registration programmes in US and Europe and launches of antibiotics, antifungals, respiratory, anti-inflammatories, lipid lowering agents, and anticancer including five she has worked on and defended within TranScrip. Previously Flic was a Regional Director of clinical research for Parke Davis and Head of Anti-infectives and she founded Gabbay Group, a CRO acquired by PPD where she became Global VP for Regulatory and Clinical Research. She was Founding Chairman of Phico Therapeutics and has also been CEO of two small biotech companies, Director of Education at the Drug Safety Research Unit in Southampton and Chairman of the steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM) and, for nine years, was its Academic Registrar. speaker profiles 15

Leslie Galloway Vice President, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Leslie built a successful career over 40 years in senior management roles in both the pharmaceutical and medical device industries, culminating in the successful turnaround of a pharmaceutical business.

He was elected EMIG Chairman in 2005 and has been instrumental in the metamorphosis of EMIG from being a business/networking group to the influential trade association it is today. In 2005, EMIG began with 17 Member Companies and today, has 240+, of which, 80% choose to be represented only by EMIG. Consequently, EMIG represents 40%+ of UK branded medicines.

In July 2014, Leslie was elected Vice President of EUCOPE. He was Vice Chairman of the NICE Project Development Group for Local Formularies Good Practice Guidance and a member of the NICE Medicines Optimisation Guidance Development Group. He is currently a member of the Accelerated Access Reference Group and a member of the Cancer Drugs Fund Working Group. He is a Member of the NHS-Industry Council, a Member of the Scottish Government’s Strategic Engagement Group, a Member of MENSA and is a visiting lecturer at the University of Cambridge.

Hakan Goker Senior Investment Director, MS Ventures

Hakan GokHa(Ph.D.) is a senior investment director at MS Ventures, the corporate venture capital fund of Merck Serono. Hakan joined MS Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Orphazyme (DK), F Star (NL), Bicycle Therapeutics (UK), Nimbus Discovery (US) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Asceneuron, Forendo Pharma, Raze Therapeutics Therapeutics, Tocopherx, Synaffix, and Progyny Inc.

Melanie Goward Deputy Fund Manager, Finance Wales Technology Venture Investments

Melanie is a Deputy Fund Manager with Finance Wales Technology Venture Investments. She manages an investment team targeting IP-rich high growth potential companies software, life sciences and medical technologies sectors and works with a portfolio of technology companies to support their growth and development. She was previously an Investment Director at NESTA, a London based technology seed fund. Melanie started her career in technology sector finance at Lloyds TSB Corporate providing debt finance to high-growth companies.

Melanie has a PhD in Genetics from Cambridge University, where she completed research forming part of the Human Genome Project. She also has a BA (Hons) in Natural Sciences.

Lars Gredsted Senior Business Analyst, Wellcome Trust

Lars Gredsted is a Senior Business Analyst at the Innovations division at the Wellcome Trust in London where his responsibilities include sourcing of new investment opportunities, contract negotiations and management & oversight of funded projects/companies including board level representation. Lars previously worked in biotech with in-licensing of early stage research projects at and as management consultant with BCG. Lars gained his PhD from EMBL/Heidelberg University in addition he holds an MPhil in Bioscience Enterprise from Cambridge University and a Master of Biochemistry from the University of Copenhagen. 16 speaker profiles

Eva Haas Senior Consultant, Investor & Public Relations, Hume Brophy

Eva Haas is responsible for Investor Relations and Public Relations in Hume Brophy’s varied International Healthcare Practice serving companies large and small. She has 20 years’ experience in fund management and equity analysis of companies across the global healthcare sector. Most recently she was at Schroder Investment Management for 13 years, of which 7 were in New York, where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in the USA. Eva has a PhD from Bristol University. She is also a fluent German speaker.

Simon Haworth Entrepreneur

Dr Simon Haworth is an entrepreneur who spends most of his time engaging with China and his family has been trading with China for 6 generations. Simon established a Chinese subsidiary for bioinformatics company CompanDX in Wuhan, Hubei Province in 2013, began in-licensing UK pharma assets for development in China through Dynasty Biotechnology in the same year and has now established The Sino-UK Fund designed specifically to invest Chinese capital to European healthcare and cleantech projects.

Sarah Haywood COO, MedCity

Sarah Haywood became Chief Operating Officer of MedCity in October 2014, after fulfilling the role in an acting capacity since its launch in April 2014 alongside her position as Head of Life Sciences at London & Partners.

She is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit, located on the UCL campus.

From there, Sarah joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners where she worked with Dr Eliot Forster to establish MedCity.

Sarah has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.

Christian Hill Managing Director, MAP BioPharma Limited

Christian Hill is Managing Director at MAP BioPharma and a Director of MAP MedTech and MAP Market Access. MAP provides market access guidance for biotech, pharmaceutical, medical device, diagnostics and vaccines businesses in the Europe and beyond.

Christian has over 18 years of experience in the life sciences industry, holding senior market-access- related positions at companies including Genzyme, Pfizer, Gilead Sciences and InterMune. He also serves on the board of EUCOPE, an EU trade organisation. speaker profiles 17

Jackie Hunter CBE CEO, BBSRC

Jackie Hunter is the Chief Executive of the BBSRC, the main funder of the UK’s bioscience research and training. BBSRC aims to promote innovation in the bioeconomy, fostering interactions, collaborations and technology transfer. BBSRC funds excellence in all areas of bioscience but also has 3 strategic priority areas, one of which is bioscience for health. Jackie’s background is in drug discovery and development and she has broad experience of industry-academia interactions.

Daniel Janse Senior Director of New Ventures, Johnson & Johnson Innovation

Daniel is Senior Director of New Ventures at Johnson & Johnson Innovation, London. Previously, he was an Investment Manager at a life sciences VC fund, ran operations for a UK stem cell start-up and advised Top 10 Pharma on corporate, R&D and commercial strategy as a management consultant for McKinsey & Company. Daniel received his PhD in Biological Sciences from Harvard University and was a Presidential Fellow at the Novartis Institutes for BioMedical Research.

Rob Johnson Managing Partner, Alacrita

Prior to co-founding Alacrita in 2009, Rob was Head of Business Development at Onyvax Ltd, a London-based biotechnology company developing complex biologics to treat cancer. At Alacrita, Rob focuses on helping companies with partnering and business development for first in class or best in class therapeutics and has ongoing engagements with Debiopharm and Bristol-Myers Squibb. Rob opened Alacrita’s US office in Cambridge, Massachusetts and has lived in the US since 2012.

Declan Jones Vice President, Neuroscience Lead, Johnson & Johnson London Innovation Centre

Declan Jones, PhD is Neuroscience Lead at the J&J Innovation Centre in London. He is responsible driving drug discovery and development opportunities for Alzheimer’s disease and Mood Disorders from academic and biotech labs via direct collaborations, public-private partnerships, acquisition or investment by our corporate VC group, JJDC. Previously he spent 18 years in GSK in both internal and external drug discovery and development, finishing as Head of Research for the Centre of Excellence for External Drug Discovery (CEEDD). 18 speaker profiles

Zahid Latif Head of Health & Care, Innovate UK

Zahid’s first degree is in Pharmacy and after a year’s pre-registration training at the Glasgow Royal Infirmary, he gained membership of the Royal Pharmaceutical Sciences. He went on to study for a PhD in natural product chemistry aimed at the discovery and identification of insecticidal compounds from tropical plants. The PhD was sponsored by ICI and Zahid spent time working at the Jeallott’s Hill Research station in Bracknell.

After graduating Zahid worked for Xenova Discovery, firstly in Slough and later in Aberystwyth looking for novel plant secondary metabolites that could be used as tools for drug discovery. Following a management buy-out of the Aberystwyth labs, Zahid stayed on to work as Operations manager for the newly formed MNLPharma and took responsibility for the delivery of their compound library generation.

After 5 years in Aberystwyth, Zahid moved on to work for Wyeth as a clinical trials supplies pharmacist to gain a broader perspective of the drug development process. Prior to joining Innovate UK (formerly the Technology Strategy Board), Zahid worked for Integrin in Oban, one of the first marine biotech companies in the UK, heading up operations for 2 years. As well as looking after the research portfolio, Zahid was responsible for delivering the company’s algal toxin testing service which also included delivering a regulatory testing service for the Food Standards Agency in Scotland.

Zahid joined Innovate UK in October 2007 as Lead Technologist in Medicines and Healthcare and was promoted to Head of Healthcare in 2010.

Tom Lillie International Therapeutic Area Head for Oncology, Amgen

Tom is responsible for oncology clinical research in Phase 2 – phase 4 for the European region and oversees the clinical teams for Amgen programs in oncology and haematology.

Dr. Lillie completed his undergraduate degree in pharmacology, cell biology and immunology at Brasenose College, the University of Oxford, before earning his doctorate from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honors distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

Dr. Lillie has held a variety of clinical research positions, specialising in oncology, in pharmaceutical companies in Europe and the USA.

Eddy Littler CEO, Domainex

Dr Littler began his research career at the University of Leeds working with Ken Powell. After postdoctoral research at McMaster University in Canada and the Paterson Institute for Cancer Research in Manchester he joined the Wellcome Research Laboratories as Head of Herpes Virus Research. At Wellcome he became Head of the Gene Targets Group and following the acquistion of Wellcome by Glaxo he became Head of Antiviral Research at GlaxoWellcome.

Eddy left GSK in 2000 to join Medivir as Senior Director of Lead Discovery and Head of their UK operations. Whilst at Medivir he played a significant role in several deals, including the outlicensing of the HCV protease inhibitor (Simprevir) programme to Tibotec. The total value of deals converted at Medivir was $360M. Eddy became the Chief Executive Officer of Domainex in May 2008. Eddy speaker profiles 19

consults for a number of companies and NGOs.

Karen Livingstone Director of Partnerships and Industry Engagement, Eastern AHSN

Karen is Director of Partnerships and Industry Engagement for Eastern AHSN. Karen is also a National Director for NHS England, leading the Small Business Research Initiative (SBRI Healthcare). Karen was a Director of NHS Midlands and East and a non-exec director on the board of the East of England Regional Development Agency (EEDA) and Business Link East.

Formerly special adviser to the Secretary of State for Health, Karen has a background in communications and media.

Tim Luker Senior Director, External Innovation, Eli Lilly

Tim leads Lilly’s external advancing innovation process in Europe within Global Corporate Business Development. Tim interacts with external VC funds targeting transformational early stage research across multiple therapy areas that work with Lilly and also supports general due diligence and search and evaluate initiatives.

He is an experienced drug hunter with 16 years’ experience and is an inventor / author on >50 patent applications and publications. He has worked in spin out biotech as well as roles at Shire pharmaceuticals (Director Exploratory projects, 2011-2014) and AstraZeneca (several R&D and medicinal chemistry roles, 1999-2011), leading multiple drug discovery projects through to candidate molecules as well as providing input into early development projects and managing medicinal & computational chemistry teams.

Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager. https://uk.linkedin.com/in/timluker

Chris Maggos Managing Director, Europe, LifeSci Advisors

Chris has over 20 years of experience in the life sciences industry covering investor relations, public relations, business development, journalism, investing, and molecular neurobiology. In September 2015 Chris opened, in Geneva, Switzerland, the European headquarters of LifeSci Advisors, a leading investor relations firm. Previously, Chris founded BioConfidant Sàrl a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals.

At Addex Therapeutics (SIX:ADXN), Chris was a member of the executive management board and held the positions of Head of Investor Relations & Communication (2007-2010) and Director Business Development (2010-2013). He co-founded the Alpine Institute for Drug Discovery in 2013, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. Chris worked as: a journalist for the leading biotechnology trade publication BioCentury (2001- 2007); an Associate at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies

Keith Martin CEO, Apitope

20 speaker profiles

Keith Martin, CEO of Apitope since 2006, has enjoyed a successful career in both large and early stage pharmaceutical/biotech companies holding senior positions in R&D and corporate & business development. He has both executive and non-executive Board experience with management and leadership roles in UK, Belgium, USA & Spain. He has raised more than € 40 million in equity and grants for early stage companies and has developed products from bench to market as well as closing significant licensing deals. He has also advised on venture investments Chris Mayo Consultant - Primary Markets, London Stock Exchange Group

Chris provides guidance to technology and life science companies and their shareholders on financing strategy. He has more than 17 years of corporate finance experience in New York and London for Barclays de Zoete Wedd, Citi and Schroders and has worked on more than 40 M&A, equity and debt transactions. Prior to his consultancy role at LSE, Chris spent 3 years as an investor and Head of Strategy for an early-stage cloud networking technology company. Chris holds a First Class Honours Degree in International Business and German from Aston University, a Masters in International Affairs from Columbia University and is a CFA Charterholder.

Stephen Minger Director, SLM Blue Skies Innovations and Senior Consultant, GE Healthcare

Dr Stephen Minger was appointed the Global Director for Research and Development for Cell Technologies at GE Healthcare in 2009. Prior to this, he was the Director of the Stem Cell Biology Laboratory at Kings’ College London for 10 years. I

n 2013, Stephen was appointed Chief Scientist for GE Healthcare Life Sciences. He left full-time employment with GE in 2015 but is still a part-time Senior Consultant for GE Healthcare. He also serves as the Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for the life sciences investment community. Stephen has a PhD in Pathology/Neuroscience from the Albert Einstein College of Medicine.

Robert McMaster Chair of the Board, BC Clinical Research Infrastructure Network (BCCRIN)

Dr. W. Robert McMaster received a Bachelor and Master of Science from the University of British Columbia (UBC) that was followed by a D.Phil. from the University of Oxford. His research interests are in the areas of molecular immunology, parasitology and transplant immunology and is co-lead on a multi-million initiative “Biomarkers in Transplantation” with funding from Genome Canada/ Genome BC and the Prevention for Organ Failure (PROOF) Center of Excellence Centre. He is actively involved with national and international granting agencies including the World Health Organization, Canadian Institutes of Health Research where he serves as the Scientific Officer for the Microbiology and Infectious Diseases Peer Review Grant Committee, and the Michael Smith Foundation for Health Research, having served as Chair of the Research Advisory Council. Dr. McMaster is a Professor in the Department of Medical Genetics and was Head of the Department, 2000-2010.

Dr. McMaster also held the positions as Director of the Immunity and Infection Research Centre at Vancouver Coastal Health Research Institute (VCHRI) and Director of Transplant Immunology for British Columbia Transplant, and was appointed the Vice President Research Vancouver Coastal Health, Executive Director, Vancouver Coastal Health Research Institute, and Associate Dean of Research, Faculty of Medicine, University of British Columbia in 2010.

Dr. McMaster is currently Chair of the Board for BC Clinical Research Infrastructure Network (BCCRIN), a member of the Health Research Council of BC, a member of the National Steering Committee for the CIHR Strategies on Patient Oriented Research, a member of the Board of Directors of Transplant Research Foundation of BC and has recently been appointed as the Vice Chair of the Board for Research Canada. speaker profiles 21

David Parfrey Executive Director, Finance and Campus Operations, BBSRC

David has very strong interests in improving impact from investment in research, particularly in capabilities available to researchers, and in encouraging early stage bioscience businesses in the UK. He is active in the development of Innovation Campuses at BBSRC sites across the UK, and holds Non-Executive Directorships in two Campus operating companies. David is the Non-Executive Chair of a company exploiting a ground breaking new plant science technology developed in a BBSRC sponsored Institute, and is a Non-Executive Director in a company underpinning an exciting new Institute under development.

David holds Fellowships of: Chartered Institute of Management Accountants; Royal Society of Biology; and the Institute of Directors.

Siro Perez Managing Director, Roundcape

Siro has over fifteen years of scientific and international management experience across the whole research, development, commercialization, and investment process in new technologies.

Siro is Co-Founder and CEO of Molecular Warehouse, an mHealth molecular diagnostics platform. Siro also actively advises and co-founds start-ups through Roundcape, a boutique advisory firm, and is a Venture Partner at Hadean Ventures, a life sciences venture capital fund.

Previously, he served as CEO of ToxiMet, leading the company from a development stage start-up to a fully commercial enterprise with sales in 5 continents, and raising £5m at increasing valuations in the process.

Before joining ToxiMet, he worked investing in pharmaceutical and biotech stocks for one of the world’s leading hedge funds ($14B under management), and as Investment Manager for a global life sciences venture capital fund ($1.5B under management).

Prior to his investment career, he worked as Project Leader in the Zurich office of The Boston Consulting Group, managing strategy projects for global Pharma, Biotech, and Financial Services companies. Prior to that, he led a group in drug development and conducted research in neurodegenerative diseases at Novartis, and started his scientific career at the Cajal Institute of Neurobiology, with several publications in peer-reviewed journals.

Siro holds a Masters in Finance from the London Business School, and a PhD summa cum laude in Molecular Biology and a MSc in Chemistry with honours from the Autonoma University of Madrid. He also studied Computer Science Engineering at UNED, and speaks English, German, and Spanish fluently.

David Phillips Vice-President and Partner, SR One

David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful 22 speaker profiles

businesses deriving healthy exits for investors.

David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London

Martino Picardo CEO, Stevenage Bioscience Catalyst

Martino is the CEO of the Stevenage Bioscience Catalyst the UK’s first Biomedical Open Innovation campus. Martino has a PhD in Biochemistry from Cardiff University and spent 4 years at Baylor College of Medicine, Houston, TX. In 2004, he became Managing Director of UMIC and MICL (University of Manchester Incubator) and was previously a Board member of UKBI.. Most recently, Martino has been appointed to the Life Science Wales Hub Board as a Non –Executive

Roberto Pierini Scientist , APCure

Roberto is a cell biologist who joined APCure in January 2014. He is leading the research of new APCure products.

Roberto has a 5 year postdoctoral experience in innate immunity and host-pathogen interaction, at the INSERM (Lyon, France). Previously he studied the autophagy induction by viruses at the UEA of Norwich (UK).

Roberto obtained his PhD in cancer research at the IFR (Norwich), investigating the role of diet in the prevention of oncogenesis.

Richard Pye Corporate Development and Communications, Summit

Richard joined Summit in 2004 as a Senior Scientist and was involved in the formative development of the Company. He subsequently moved into the corporate side of the business and currently has responsibility for corporate communications, investor relations whilst also being involved with general corporate development activities including Summit’s recent listing on NASDAQ. Richard has a broad range of experience and skills and these include the fundraising on AIM and NASDAQ, securing not-for-profit financing, and M&A and divestment activities. He holds a PhD in Organic Chemistry and prior to joining Summit was a Post-Doctoral Research Associate at The University of Oxford.

Rachael Ritchie Director of International Partnerships, Genome British Columbia

Dr. Rachael Ritchie, Director of International Partnerships at Genome British Columbia, is an internationally trained scientist with two decades of experience in life science research and innovation. She has worked in America and in Europe, across disciplines and borders, supporting multidisciplinary partnerships the bring discovery research to application. From aquaculture to population health, Ritchie seeks to catalyze bioeconomy partnerships to improve the productivity, sustainability and competitiveness of individuals, businesses and communities. speaker profiles 23

Naveed Siddiqi Partner, Edmond de Rothschild Investment Partners

Naveed joined the life sciences team of Edmond de Rothschild Investment Partners in 2013. Most recently he was a Partner at Phase4 Ventures in London. Prior to this Naveed worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as medical doctor in the UK’s National Health Service. He has 22 years of venture capital, investment banking, private equity advisory and accountancy experience in life sciences and other sectors. Naveed graduated in medicine from Guy’s and St Thomas’s Hospital Medical School at the University of London. Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales. Naveed has previously served or observed on several company Boards in both Europe and United States at Nomura and Phase4 Ventures. Currently, he sits on the board of Laboratoris Sanifit

Julie Simmonds Director, Equity Research, Panmure Gordon

Julie joined Panmure Gordon in 2015 from Canaccord Genuity. Her research coverage focuses on small and mid-cap healthcare companies. Prior to that Julie worked at Piper Jaffray where she spent five years as a Senior Analyst in the No. 1 Extel rated healthcare team. Her research coverage included both small and mid-cap UK healthcare companies, including medical devices, biotechnology and services, and large-cap European stocks.

Julie has also held positions at Nomura and as Head of Life Sciences Research at Evolution Securities where she was an analyst from 1998 to 2004. Julie has a PhD in Microbiology from University of Kent at Canterbury. Prior to becoming an analyst Julie gained industrial experience in both Europe and the US.

Claire Skentelbery CEBR

Claire Skentelbery has a PhD in biochemistry and for the last 15 years has worked in the communication of science and the creation of scientific networks across Europe. In 2003, Claire was part of the team that launched the Council of European BioRegions (CEBR), which is a network of clusters across Europe with the aim to defragment the cluster development and to connect SMEs between clusters on a global scale. Claire continues to manage CEBR, and networks clusters around the world.

In 2010, Claire also took on the role of Secretary General of the European Biotechnology Network (EBN), a network with the mission to build partnerships. With almost 2000 members, EBN works to build scientific partnerships across sectors and organisation types, with a strong focus on SME- driven collaboration for effective maturation of science, making use of collaborative funding as a tool to drive partnerships.

Clare Terlouw Managing Director, Corporate Broking and Advisory, Numis Securities 24 speaker profiles

Clare has over 17 years experience in the healthcare industry including 11 years as a specialist healthcare banker. Clare advises growing life science and healthcare companies on a range of transactions including IPOs, secondary fundraisings, private placements and M&A. She has a particular interest in biotech, specialty pharma, medical devices and medical technology. Prior to joining Numis, Clare held positions at Peel Hunt and Nomura Code. She also worked as an orthopaedic physiotherapist for 4 years. Ingrid Teigland Akay Managing Director, Hadean Ventures

Ingrid Teigland Akay is a medical doctor, entrepreneur and investor with experience within healthcare, consumer goods and technology. As a medical doctor, she has a broad clinical background from general medicine and surgery, working internationally in both the public and private sector. As a venture capitalist, Ingrid has substantial experience from deal sourcing, investing, and supporting start-up companies globally in different phases of development, from R&D to commercial stage

Nicola Thompson Head of Office of External Drug Discovery, Roche

Nicki is Head of Roche’s Office of External Drug Discovery, focusing on delivering preclinical assets to all of Roche’s therapy areas in partnership with early-stage Biotechs and entrepreneurs. In her previous role at GSK, she was Senior Director, Business Development for GSK’s Ceedd (Centre of Excellence for External Drug Discovery), complementing and innovating internal drug discovery and development through external partnerships. Nicki is an experienced drug discoverer in both large Pharma and Biotech settings.

Mark Thompson Partner, Sidley Austin

Mark Thompson has over 20 years of experience advising clients on international M&A and private equity transactions. Recognized as a leader in his field by Chambers, Best Lawyers in the UK, The Legal 500 UK and London Super Lawyers, Mark has extensive experience advising clients making investments in the U.S., Western and Eastern Europe, Russia and the Middle East. He represents private equity funds with respect to their investment activity, as well as fund sponsors in the formation of those funds. The LMG Life Sciences Guide lists Mark as a “Life Sciences Star” for M&A and corporate and commercial work in the industry.

Mark Treherne CEO, UK Trade & Investment Life Sciences Organisation

Dr Mark Treherne is Chief Executive of the Life Sciences Organisation, which was established by UK Trade and Investment (UKTI) to support overseas investment into the UK: from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships. Mark now has over 25 years’ experience of commercialising R&D in public and private pharmaceutical and biotechnology companies.

Abel Ureta-Vidal CEO, Eagle Genomics

With a scientific background in molecular biology and immune-virology including a PhD from the Pasteur Institute, France, Abel first mastered bioinformatics tools and code in the early 1990s whilst working on viral phylogenetic studies. After his PhD, he joined the effort at Genoscope (Evry, speaker profiles 25

France) in ramping up the Human Genome Project, putting in place the automatic gene annotation system for human chromosome 14. In 2001, Abel moved to the European Bioinformatics Institute (EBI) where he led the Ensembl comparative genomics team until 2007. He founded Eagle Genomics shortly before graduating from the Cambridge Judge Business School MBA program in 2008.

Louise Ward Partner, Commercial Real Estate, Charles Russell Speechlys

Louise is a Partner in the Commercial Real Estate department of Charles Russell Speechlys LLP. She handles a wide variety of matters, acting for a mix of investors, developers and corporate occupiers across a number of real estate sectors on work including sales, purchases, pre-lets and leases. Louise has developed particular expertise in advising new entrants to the UK real estate market, for both investment purposes and for their own occupational needs. In the Life Sciences Sector, Louise acts for BioMed Realty, L.P, owner of Granta Park in Cambridge.

Tom Weaver CEO, Congenica

Tom is interested in applying ‘omics technologies to healthcare. Commercial - founded Congenica Ltd, a genome diagnostics company, in 2014 and was part of genomic start-ups Hexagen and Geneservice, both successfully sold to publically traded companies, including Incyte (NASDAQ) and Source Bioscience (LSE) where he served on the board as Commercial Director. Academia: MRC (Director), MRC LMB, University of Cambridge (NIH and WT Fellow), and University Wisconsin (PhD Oncology, BSc Mathematics, Biochemistry).

Robert Wilkinson Director of Cancer Research, MedImmune

Dr Robert W. Wilkinson, Director of Cancer Research, MedImmune Ltd. Robert has over 20 years of experience in biotech/pharmaceutical industries, in both small and large molecule cancer drug discovery. He is currently Director of Oncology Research at MedImmune (Cambridge), the biologics arm of AstraZeneca, and is charged with the generation and delivery of new candidate biotherapeutics. His team, uses the latest therapeutic strategies (incl. antibody and protein based platforms, oncolytic virotherapy and oligonucleotides) and is focused on immunotherapies, as well as tumour targeted therapies (incl. antibody-drug conjugates). Molecules to come out of the group include the anti-PD-L1 antibody, Durvalumab (MEDI4736).

Tony Young National Clinical Director for Innovation, NHS England

Tony has been a medical innovator and entrepreneur throughout his career. He has established four MedTech companies and raised over £5m in private sector financing for these. He has been a Consultant Urological Surgeon at Southend Hospital since 2007 where his specialist clinical interests include stone disease and laser prostate surgery.

In 2010 he was appointed as Director of Medical Innovation at the Postgraduate Medical Institute at Anglia Ruskin University. He is leading on research, development and commercialisation of new medical devices and developing new educational programmes in this area. Through his role at the PMI he has been instrumental in bringing together the partnership that forms the Anglia Ruskin MedTech Campus. This will become one of the world’s largest health innovation spaces and will help transform the UK MedTech sector. . In addition to this in the last 4 years Tony has been a member of a number of committees/oversight/ expert review/task and finish groups for the Department of Health, NHS England, Public Health England, NIHR and Essex County Council. This work has focused on helping to deliver innovation across the NHS.

In September 2014 he was appointed as National Clinical Director for Innovation at NHS England. In this role he provides clinical leadership and support in delivering improved health outcomes across the 5 domains of the NHS outcomes framework. In particular he is focussing on driving the uptake 26 programme

08.00 Registration

08.00 - 09.00 Breakfast Sessions Albert 2nd floor Albert, 2nd Floor Victoria, 2nd Floor Supporting Life Sciences in GLE Briefing: Trends in Life Science London, Oxford, Cambridge: A MedCity Investment Update Sarah Haywood Chris Farmakis Chris Mayo MedCity GLE Group London Stock Exchange

09.00 Opening of Genesis Whittle, 3rd Floor

09.00 - 09.15 Welcome from One Nucleus Harriet Fear CEO, One Nucleus 09.15 - 09.40 Investing in Innovation Richard Mason Johnson & Johnson Innovation

09.40 - 10.05 Winners and Losers in the Life Science Industry 2015 Mike Ward SCRIP Intelligence and Datamonitor

10.05 - 10.55 Plenary Panel Debate: Are Public Market Technology Transfer Funds Changing Innovation Funding? Chair Panellists Chris Mayo Chris Maggos Eric Elenko Tom Hinton David Pinniger London Stock Exchange LifeSci Advisors PureTech SyndicateRoom Ploar Capital

10.55 - 11.00 Closing remarks from the Chair

11.00 - 11.30 Coffee break 11.30 - 12.30 Parallel Sessions I

Westminster, 4th floor Moore, 4th floor Victoria, 2nd floor Albert, 2nd floor Case Study Deals - Technologies Empowering Funding an Innovative International Growth Immunocore - Eli Lilly use of -omics for Data-driven Science Base Strategies: North America Discovery and Validation

Chair Chair Chair Chair Mike Ward Abel Ureta-Vidal Davidson Ateh Rob Johnson SCRIP Intelligence Eagle Genomics BioMoti Alacrita Consulting Speaker Panellists Panellists Panellists Eva-Lotta Allan Rachael Ritchie Zahid Latif Eddy Littler Immunocore Genome British Columbia Innovate UK Domainex

Craig Tucker Panellists Tom Weaver Jackie Hunter CBE Pennsylvania Bio Naveed Siddiqi Congenica BBSRC Edmund de Rothchild Investment Satu Vainikka Fund Michael Barnes Rob McMaster Valirx The Farr Institute VCH Research Institute Hakan Goker Jane Dancer MS Ventures Aisling Burnand MBE F-Star Sue Charles Association of Medical Research Instinctif Partners Charities Astrid Maria Dahl AstraZeneca

Lars Gredsted Wellcome Trust

12.30 - 14.00 Lunch

12.40 - 13.30 Lunch Keynote Address and BioNewsRound Award

12.40- 13.00 Introduction to the Life Sciences Organisation (LSO) Mark Treherne UK Trade & Investment Life Sciences Organisation programme 27

13.00 - 13.20 Lunch Keynote Address George Freeman MP Minister for Life Sciences 13.20 - 13.40 Presentation of the BioNewsRound Award 2015

14.00- 15.00 Parallel Sessions II

Westminster, 4th floor Moore, 4th floor Victoria, 2nd floor Albert, 2nd floor Case Study Deal - Johnson Future of Immuno-Oncology Generating an International Growth & Johnson Innovation Infrastructure for Strategies: Europe - Alligator Bioscience Innovation Pharmaceuticals

Chair Chair Chair Chair Mike Warrd Robert Wilkinson Steve Bates Claire Skentelbery SCRIP Intelligence MedImmune BIA CEBR Speakers Panellists Panellists Panellists David Colpman Tom Lillie Martino Picardo Mark Craighead Colpman Consulting Amgen Stevenage Bioscience Catalyst Redx Pharma

Daniel Janse Roberto Pierini Sally Ann Forsyth Keith Martin Johnson & Johnson Innovation APCure Norwich Research Park Apitope

Panellists Namir Hassan David Parfrey Leslie Galloway Melanie Goward Immunocore BBSRC EMIG Finance Wales Kieron Flanagan Clare Terlouw Manchester Business School Numis Securities Louise Ward Siro Perez Charles Russell Speechlys Roundcape

15.00- 15.20 Coffee break

15.20 - 16.00 Plenary Session - Introducing the Dementia Discovery Fund

Chair Panellists Kate Bingham Tim Luker Declan Jones Mark Carlton Laurence Barker SV Life Sciences Eli Lilly Johnson & Johnson Innovation Takeda Cambridge GlaxoSmithKline

16.10- 17.10 Parallel Sessions III

Westminster, 4th floor Moore, 4th floor Victoria, 2nd floor Albert, 2nd floor Case Study Deal - Mereo Funding, Developing and Improving Market Access Can you Fund your Research Biopharma - Novartis Launching New Antibiotics to Enhance Innovation with Chinese Capital? and Anti-cancer Agents Funding

Chair Chair Chair Chair Mike Ward Flic Gabbay Morris Berrie Simon Haworth SCRIP Intelligence TranScrip Partners TS Global Initiative University Dynasty Biotech Speaker Panellists Speaker Panellists Denise Scots-Knight Nicola Thompson Tony Young Graham Ball Mereo Biopharma Roche NHS England CompanDX Panellists Renata Crome Stephen Minger Cancer Research UK Panellists SLM Blue Skies Innovation Julie Simmonds Christian Hill Panmure Gordon Richard Pye MAP BioPharma Summit Ingrid Teigland Akay Karen Livingstone Hadean Ventures Eastern Academic Health Science Network (EAHSN) Eva Haas Hume Brophy

17.15 - 18.15 SCRIP – One Nucleus Plenary Debate: Trends in M&A and their Impact Whittle Chair Panellists Mike Ward Mark Thompson John Burt David Phillips Shaun Grady SCRIP Intelligence Sidley Austin Abzena SR One AstraZeneca

18.15 - 19.15 Drinks reception

19.15 Close 8 9 10 11 7

Fleming Digital delegate The Farr Institute photo board Industry Forum 6 51 52 St James 4th floor 5 50 Whittle Break Out Sessions 4 Bio Cafe Partnering Albert 2nd floor 3 Victoria 2nd floor Moore 4th floor 2 Westminster 4th floor

1 Pi

Key

18 17 16 15 14 13 12 i Help desk

Pi Partnering desk

Catering Lifts i Toilets 47 Lifts 48 46 45 Fire Exits 44 Lifts 19 Partnering Photos 20 43 42 41 49 23 22 21 Britten The Global Cluster HS Hub H4 Source 24 30 31 34 37 H3 - 6 Lounge 25 29 32 35 38 H2 H7 H12

H1 28 33 36 H8 26 27 39 40 H9 H10 H11 exhibitor list 29

1 TranScrip Partners 27 ils Intelligence HS Source Lounge - MedCity floor floor 2 Global Data 28 H4 - H6

floor ICHP, UCLP, HIN AHSNs

floor ERA Consulting th th nd nd 3 Page, White and Farrer 29 Zyme Communications H7 Guy’s & St Thomas’ NHS Foundation 4th floor 2 2 4 R.G.C.C. International 30 Jumpstart Trust 5 Eagle Genomics 31 Forresters H8 SBRI Healthcare Help desk Help Catering Toilets Exits Fire Partnering Photos Partnering desk 6 Fahy Gurteen Laboratories 32 SCRIP Intelligence H9 Oxford AHSN 7 BioHub Birmingham 33 Lilly H10 King’s College London 8 34 i Envigo APL H11 Imanova Pi Key

The Farr Institute Institute Farr The Industry Forum James St 9 Westminster 4 Westminster Victoria Victoria 4 Moore Break Out SessionsBreak Albert London Bioscience Innovation Centre (LBIC) 35 Avacta Life Sciences H12 Imperial Clinical Trials Unit 10 UK Trade & Investment 36 Dora Wirth (Languages) Ltd 11 Life Science Hub Wales 37 Manchester Science Partnerships (MSP) Get Ready for JP Morgan 2016 12 Sequani 38 HS New Scientist Jobs H1 Hume Brophy 13 Norwich Research Park 39 Pharmidex Flight Centre Business Travel 14 Bio-Rad Abd Serotec 40 Pharma Publications United Airlines 15 Stockholm-Uppsala Life Science (SULS) 41 Mathys & Squire LLP Biopartner H12

H11 16 Boyds 42 Syne qua non Ltd EBD Group 17 Sidley Austin LLP 43 Nova Language Services Ltd

H10 18 Government of South Australia 44 KISS Communications Preparing for Start-Up and High Source Lounge 19 Flanders Investment & Trade 45 QuickSTAT Growth

H9 20 Scottish Development International 46 Bridge Partners H2 Agility Health Tech Partnering

Pi 21 AstraZeneca 47 Illingworth Research Moore Stephens - 6 H4 H7 H8 12 22 UMI3 48 Canadian High Commission Penningtons Manches 23 Abzena 49 United Life Sciences Global Regulatory Services H3 H2 Digital delegate delegate Digital board photo 24 50

11 First Sight Media GLE 13

41 H1 25 The Farr Institute Industry Forum 51 RIFT Group Outsourcing R&D 26 World Courier 52 Creative Places H3 Hartswood Media 14

42 Assay Depot 40 Lifts

Lifts 52 15 39 43 10 37 38 Cafe

51 16 44 9

Bio

Fleming 50 34 35 36 45 17 8 genesis fringe events 18 46 Britten

7 At last year’s Genesis event we brought a new concept to our conference, called the ‘Genesis Fringe’. This arose because we were increasingly 47 approached to ask if we could promote an event being delivered on the days either side of Genesis in order to capitalise on the opportunity of 31 32 33 and for Genesis visitors being in London. The fringe proved such a success that we have brought it back for you for Genesis 2015. 6 5 4 3 2 1 This year we are supporting a number of events as part of the Genesis 2015 Fringe including: 30 29 28 DEC UK HealthTech Conference DEC Personalised Medicine - Putting patients at the centre

i 01 Organised by MediWales, SEHTA and GLA 09 Organised by Bristows 48 20 19

27 21

26 DEC Accessing US Capital In Life Sciences

24 25 Organised by Sullivan & Cromwell LLP, London DEC Cell Therapy Seminar at the Shard 22 01 Lifts Stock Exchange, RBC Capital Markets and 09 Organised by Maria-Joao Martins Clermont 23

DEC London MedTech: Innovation and Investment Getting it Right: The Role of Smart Technologies and 03 Trends DEC Data Analytics in Patient Adherence. And Genesis Organised by MedCity, SEHTA and GLA 09 49 Welcome Reception Joint Anglia Ruskin MedTech Campus – One Nucleus Whittle DEC Seminar The Future of Healthcare Hub

07 Organised by London Business School DEC 09 Asia Pacific Life Sciences Clinic Organised by UK Trade & Investment (UKTI) London The Global Cluster Global Cluster The DEC LES Young Members Event Organised by LES 09 If you are interested in promoting an event as part of the Genesis 2016

Fringe, please contact [email protected] >     32 source lounge

The Source Lounge

The Source Lounge at Genesis 2015 sponsored by MedCity is a dedicated space located within the Britten room packed with some of the key access points to the biomedical research, clinical excellence and funding sources available across London, Oxford and Cambridge. In the Source Lounge you will find representatives from all three of the London Academic Health Science Networks, and the Oxford area AHSN, alongside representative from leading organisations like Imanova, Guys and St Thomas’, the Imperial Clinical Trials unit and SBRI. The theme pulling all these together is maximising healthcare innovation through partnership and engagement.

In addition we have three focussed business hubs, see below. This is a unique opportunity for all delegates to explore partnership opportunities, receive expert advice, have 1-2-1 clinics and find out about savings on out-sourcing, conferences and travel.

H4 - H6 ICHP, UCLP, HIN AHSNs H9 Oxford AHSN H12 Imperial Clinical Trials Unit H7 Guy’s & St Thomas’ NHS Foundation Trust H10 King’s College London H8 SBRI Healthcare H11 Imanova Outsourcing R&D

Sponsored by Hartswood Media and Assay Depot

Critical to an effective out-sourcing strategy is the ability to identify the right vendors and implement a robust and efficient procurement process.

One Nucleus together with Hartswood Media and Assay Depot have launched two major initiatives which aim to enable our members to meet these goals. Meet Hartswood Media and Assay Depot at H3 and find out more about these initiatives and what they can offer you. Preparing for Start-Up and High Growth

Supported by Global Regulatory Services and Agility Health Tech

Critical to building long term success are solid foundations and robust strategies. Delegates are offered the opportunity to meet privately for:

• A free 30 minute private 1-2-1 clinic with experts from Agility Health to rehearse and critique the positioning and presentation of their business and product development strategy • The opportunity to meet with Tax and Grant experts from Moore Stephens around available incentives and funding • The opportunity to meet with legal experts from Penningtons Manches • The opportunity to meet with Global Regulatory Services to discuss how to optimise their development pathway options

Companies represented in the Innovation Hub can be found at H2 and include: Agility Health Tech, Moore Stephens, Penningtons Manches and Global Regulatory Services.

Get Ready for JP Morgan 2016

Sponsored by Hume Brophy Supported by the Flight Centre

The week commencing 11 January 2016 is once again set to be a vital point of the year for Life Science companies and investors as they head to San Francisco for the JP Morgan and Biotech Showcase Conferences. One Nucleus and Hume Brophy are keen to ensure attending companies maximise the impact on their business by providing access to expertise, savings and connections to aid your preparation. Exhibiting at H1 delegates are offered the:

• Opportunity to have a free 30 minute private 1-2-1 clinic with Investor Relations experts from Hume Brophy to rehearse and critique your presentation ahead of JPM • Opportunity to find out what One Nucleus members are saving on the flight and hotel costs via Flight Centre Business Travel and United Airlines • Opportunity to hear about discounts on the delegate fee to attend EBD Group’s Biotech Showcase via BioPartner UK • Opportunity to find out how to leverage One Nucleus collaborations with key US clusters You command connections.

The in-market resources that come with World Courier’s unsurpassed knowledge, global reach and flawless supply chain execution mean that whether your product is going across town or across the world, you can trust us with what matters most: your commitment to improving global health.

Choose confidently. Choose World Courier.

Learn more at worldcourier.com.

195_Journal_Print_Ad_210x297_r1.indd 1 8/7/15 11:48 AM 34 exhibitors

AstraZeneca is a global, innovation- APL is one of the leading Scandinavian The Abzena group (PolyTherics, Antitope driven biopharmaceutical business that contract manufacturers (CDMOs) with 550 and PacificGMP) have established a suite focuses on the discovery, development and employees and four sites, all located in of complementary technologies designed commercialisation of prescription medicines, Sweden. APL’s facilities are well suited for to assist in successful development of primarily for the treatment of cardiovascular, manufacturing niche products in commercial antibodies and proteins with enhanced metabolic, respiratory, inflammation, scale as well as clinical trial materials. We therapeutic benefits. With specialties in autoimmune, oncology, infection and manufacture in cGMP grade facilities, which site-specific conjugation technologies neuroscience diseases. AstraZeneca operates are regularly inspected by EMA, FDA, and for ADC development, optimization in over 100 countries and its innovative customers corporate QA. APL develops of the therapeutic properties of medicines are used by millions of patients and manufactures in most formulations, biopharmaceuticals, immunogenicity worldwide. from aseptic sterile injection solutions assessment, antibody humanization and to non-sterile capsules and semi-solids. deimmunisation of therapeutic proteins We offer high competence and extensive as well as cell line development and GMP resources for a broad range of chemical manufacturing for Phase I and II clinical trials. and microbiological analyses, as well as The group has built a global customer base, develop and validation of analytical methods including the top 10 pharma, large and small according to ICH Guidelines. biotech, and academic groups.

astrazeneca.com Ayesha Bharmal Director, Business apl.se Development and Partnering Mattias Nyström, Business Development CommunicationsAyesha.Bharmal@ abzena.com Manager astrazeneca.com Neil Butt, VP Business Development [email protected] Stand 21 [email protected] Stand 34 Stand 23

Avacta Life Sciences Affimer® reagents are The BioHub Birmingham® AbD Serotec, a Bio-Rad company, is affinity proteins, based on a small protein Established in March 2015, The BioHub an expert manufacturer and supplier of scaffold engineered to bind with high Birmingham® is the first purpose-built antibodies for drug discovery, clinical specificity and affinity to a range of targets. facility of its kind in the UK. Based within diagnostics and academic research. Whether With a 7 week custom service and an online Birmingham Research Park, it forms part of you need a ready-made product, a complex catalogue, Affimers are used for various a thriving community of entrepreneurial custom antibody generation project, or applications in diagnostics, drug/biomarker businesses and academic researchers, small to bulk manufacturing and purification discovery, biotech R&D and as therapeutic offering the best possible ecosystem services, we cater for all requirements. No agents. to develop biomedical innovations. An other company can rival our unique custom impressive 4,500 sq.ft of biomedical recombinant monoclonal antibody service laboratory space is shared by tenants, along that generates highly specific, high affinity with tissue culture rooms, microscopy lab, Fab antibodies with >90% success rates in sterilisation equipment, and a cryogenic only 8 weeks. We aim to help you reach your suite. Desk space is also provided, along with goals by providing the antibodies you need the business advice and guidance which and a professional, long-term partnership for avactalifesciences.com will be critical as your ideas move from the success. For further information visit www. Dan Gare, Senior Business Development innovation and research phases to become abdserotec.com. Manager market-ready commercial products. [email protected] +44 (0)1904 217046 Stand 35 thebiohub.co.uk abdserotec.com Helen Miller-Viney – Business Development Chris Bullion, Antibody Sales Specialist Manager [email protected] [email protected] Stand 14 +44 (0)121 4 15 8543 Stand 7 exhibitors 35

Boyds was established in 2005 and Bridge Partners and Bridge Fibre are sister Canadian High Commission. The UK is by provides a range of expertise and skills companies working together to provide first far Canada’s most important commercial central to support the development of your class IT services. Based in Cambridge with 15 partner in Europe and the Commercial pharmaceutical & biotechnology medicinal years’ experience of delivering on our core and Economic Division of the Canadian products and medical devices. values of Clarity, Partnership and Quality. High Commission in London works with We are based in the UK with offices in Canadian companies, research institutes Cheshire and Cambridgeshire. Bridge Partners are a trusted partner offering and universities that are seeking market Our consultancy services offer a cost- outsourced IT support. Our professional, opportunities or commercialisation, effective solution for those requiring expert friendly team delivers tailored services: from licensing and R&D partnerships. We also offer assistance in order to expedite development, hands-on technical support to top-level confidential advice and service to British add value to their product and reach those strategy giving our client time to focus on companies interested in investing in Canada milestones. their business goals. or in finding Canadian collaborators. We have expertise in the development and commercialization of medicinal products Bridge Fibre is a fast-growing across a broad range of therapeutic areas. communications technology company Professional Services delivering a range of ISP services designed • Product Development for Business Parks & their tenants. We • Regulatory Affairs specialise in providing cost-effective, high- • Regulatory Medical Writing speed internet connectivity, IP telephony and • Statistics and Data Management hosted services. • Medical Monitoring Support • Business Support bridgepartners.co.uk Stand 48 • Training Alastair Mundell • Due Diligence Activities 44+ (0)1223 750150 boydconsultants.com Stand 46 Stand 16

Creative Places are property advisers DWL combines specialist translation Eagle Genomics accelerates the working across the UK to help clients create services for the life science, pharmaceutical, opportunities offered by genomics and new business environments that enhance biotechnology, medical technology and data generation technologies to address innovation. medical device industries with in house some of the world’s key challenges in medical expertise, a proven track-record healthcare, infectious disease, personalised News for 2016 is that we have agreed to work of dedication to the field, and a strong medicine, livestock and crop development, with MedCity on a Life Sciences R&D Demand commitment to quality and service. food quality and production, green energy Study, involving leading research institutions. and water recycling. We seek to understand what the sector most DWL has over 50 years’ experience in needs and guide on how opportunity can be providing global translation solutions and increased. We encourage participation by language consultancy, in the following businesses interested in working with others. specialist areas: We believe this can truly help the London, Cambridge, Oxford triangle. Please find our • Regulatory Affairs stand and join us. • Clinical Research • Medical Research • Medical Publishing • Manufacturing • Medical Devices • Legal • Marketing Communications

Stand 52 dwlanguages.com eaglegenomics.com Kim Shouler, Business Development Director Michael Reynolds [email protected] [email protected] Stand 36 +44 (0)1223 654481 Stand 5 36 exhibitors

Envigo, one of the world’s leading global ERA Consulting has served the Fahy Gurteen Laboratories is a contract research organisations, and biopharmaceutical industry for over 28 years, histopathology service provider to biotech, products and services company, is dedicated providing regulatory, strategic and technical academia and the NHS. to helping our customers achieve the guidance for the development of medicinal With an extensive quality management potential of their products and enhance life agents (>450 to date), including ATMPs (cell/ system at the heart of everything we do, through the development of new medicines, tissue/gene therapies including stem cell we supply an unparalleled service from greater food production and a safer therapies), recombinant protein/antibody routine histology to whole slide scanning environment. We set the highest standards therapeutics, vaccines, natural products and advanced automated image analysis. and offer a broad range of practical support, and small molecules. Our expertise covers Fahy Gurteen R&D department also holds consultancy and problem solving, all of quality, nonclinical and clinical aspects, patents for a novel cell cycle cancer test with which can be tailored to meet your specific both from the regulatory and development prognostic and predictive indications, for needs. With locations across the world, you strategy perspective. Our specialised which we are actively seeking development will always have access to our experts when international team of more than 30 full-time partners. you need them. professionals includes consultants drawn from biotech, pharma, biomanufacturing, regulatory, translational medicine and academic scientific backgrounds to provide experienced support from product inception through development to commercialisation. fglabs.com eraconsulting.com Dr Saroj Velamakanni, Principal Scientist & Adam Levy Research Director envigo.com [email protected] [email protected] [email protected] +44 (0) 20 7510 0200 +44 (0) 1223 205040 +44 (0) 1480 892 000 Stand 28 Stand 8 Stand 6

The Farr Institute of Health Informatics First Sight Media. As a video production and Flanders Investment & Trade (FIT) is a Research comprises four nodes distributed streaming specialist, the professional team governmental agency and part of the Belgian across the UK and led from the University at First Sight Media have been delivering Embassy. With over 90 offices worldwide College London (Farr Institute @ London), creative live events, training and promotional our core focus is to maximise business University of Manchester (Farr Institute videos for over 20 years. Specialising in opportunities by working in the interests @ HeRC N8), Swansea University (Farr live and on-demand video streaming, of both overseas and Flanders-based Institute @ CIPHER), and the University of communicating your message through us, companies. Dundee (Farr Institute @ Scotland). With a over the internet has never been easier. Our services include helping UK-based £17.5m-research award from a 10-funder We also offer the ability for you to enhance companies to set up an office, finding a consortium, plus additional £20m-capital your conferences and webinars through our partner, establishing relationships and aiding funds from the Medical Research Council, bespoke presentation software iPresenter, with funding in Flanders. the Farr Institute aims to deliver high-quality, allowing you to deliver high definition video With top European universities, a world- cutting-edge research linking electronic of your speaker simultaneously with their class reputation in innovative research health data with other forms of research presentation slides online. and pioneering life science hubs, Flanders and routinely collected data, as well as build Whatever your audience, we can offer a is a prime location for bio-innovation. capacity in health informatics research. The tailored solution to effectively communicate We can help if you’re looking to establish Farr Institute aims to provide the physical your message through creative multimedia. your European headquarters, partner and electronic infrastructure to facilitate Visit our website to see examples and get in with life science experts or explore further collaboration across the four nodes, support touch. possibilities of research. their safe use of patient and research data for If you would like to find out more about our medical research, and enable partnerships firstsightmedia.co.uk services, please do not hesitate to contact our by providing a physical structure to co-locate Mike Gilham, Sales Director office in London or take a look at our website NHS organisations, industry, and other UK [email protected] at www.investinflanders.com. academic centre 0800 072 8753 Stand 24 investinflanders.com Stand 19 farrinstitute.org Stand 25 exhibitors 37

Enterprise Europe Network is your gateway At Forresters, we provide clear, sensible and GlobalData is a one-stop solution for to competitiveness and innovation. The practical advice on intellectual property, actionable insight into the pharmaceutical Network supports businesses to make the including patents, trade marks, designs and and medical device sectors. Together with most of the opportunities in the European copyright, in the UK and across the world. the best team of researchers, analysts, market. We help local organisations to find epidemiologists and consultants, and an the right business partners, build their We like to take a collaborative approach with unmatched suite of proprietary databases, innovation capacity and meet their capital our clients, drawing on their knowledge to we provide high-quality, accurate and requirements. ensure that we understand what they want transparent insight that can help you achieve to achieve. We look to deliver our guidance growth and increase business value. Enterprise Europe Network is strong of in plain, jargon-free language and are not Our valuable research and consulting approximately 600 business support afraid to recommend a particular course of solutions ensure you stay at the forefront of organisations in 54 EU and non-EU countries, action, if we think it is right for you. We have the industry by integrating accurate market promoting international cooperation locally. a well-established and sizeable life-sciences forecasts and healthcare analytics on the Our services are specifically designed for department, with extensive experience in latest trends and developments. Among Small and Medium-sized Enterprises (SMEs) getting and litigating patents in the UK and other benefits, our informed healthcare but are also available to all businesses, Europe. industry perspectives have assisted research centres and universities across businesses based across the pharmaceuticals, Europe. biotechnology and medical equipment forresters.co.uk markets in making strategic decisions that Charlotte Teall have increased the value of their products [email protected] and services. een-london.co.uk Stand 31 Stand 2 [email protected] Chris Farmakis , EC Funding Manager Stand 50

Health Industries South Australia guides Illingworth Research is a full service clinical Insights in Life Sciences (ilS) is a global the growth of the biotechnology and medical CRO with experience across all phases Life Sciences consultancy firm, specialized technology sectors in Adelaide, South of development from Phase I / proof of in all existing Primary Research solutions Australia. A$3.6 billion has been invested in concept studies to post-marketing studies (ilS SolutionsSM). It provides Life Sciences the new “Adelaide BioMed City” cluster which for small molecules, biotechnology products, companies with unique access to a broad includes the South Australian Health and medical devices and diagnostics. With a range of Life Sciences Experts recruited by Medical Research Institute (SAHMRI), the new network of clinical infrastructure covering pre-defined knowledge and compliance 800-bed Royal Adelaide Hospital, two new most therapeutic areas varying from clinical criteria. Through ilS Primary Research University buildings, and SAHMRI 2 which research units, primary, secondary and Solutions (including in-depth phone is planned to host Australia’s first proton tertiary care sites across Europe and with interviews, online surveys and expert onsite therapy unit. Adelaide BioMed City will be partners in North America and Australasia, panels) companies can access remarkable the largest cluster of its type in the Southern Illingworth has the capability to deliver insights directly from world´s top experts. Hemisphere, employing 8,000 staff, including large multi-centre global studies on time Leveraging on these insights, ilS allow Life 1,500 world class medical researchers. Fast and within budget. Illingworth Research Sciences companies to create and execute approvals and generous R&D cash back also provides research nurses for patient optimal Pricing and Market Access strategies incentives make Adelaide an ideal location homecare to support studies for optimisation thus achieve a competitive advantage. for your next Clinical Trial. of patient retention and compliance. Illingworth also offers a medical photography ilsintelligence.com service. [email protected] Itziar Escudero, Partner at Insights in Life Sciences healthindustries.sa.gov.au/Jason. illingworthresearch.com [email protected] Jason Cameron, Trade & Investment Manager John Illingworth, Managing Director Pepi Hurtado, Partner at Insights in Life [email protected] [email protected] Sciences Stand 18 Stand 47 [email protected] Stand 27 38 exhibitors

Jumpstart is a specialist R&D tax advisory KISS is the creative agency that clarifies the The Life Sciences Hub is the nerve centre of firm. complex. We work with ambitious brands a vibrant and prosperous Welsh Life Sciences We work with all sizes of companies across that passionately believe they can change eco-system and brings together academic, all sectors, as well as with accountants, the world and need an agency that can business, clinical and professional services on all stages of their R&D claims. Clients deliver. and funding organisations to provide a appreciate how we minimise their time, risk With specific and in-depth expertise in commercially-driven melting pot of talent. and complexity through the process as well Healthcare, Science, Technology and FMCG By encouraging research & development, and as maximising the compliance and value for our ability to cut through complexity providing access to finance and expertise, them. and successfully deliver a single-minded the Hub showcases Welsh Life Sciences Our success comes from our scientific and proposition has been instrumental in us globally for success in health and wealth. technical approach, and we use our own winning a fantastic range of blue chip, SME The Hub’s unique space is designed to the experts, including chemists, biologists, and disruptive start up clients. highest standards, stimulating collaboration, physicists, computer scientists and software We are strategy led and successfully integrate innovation and investment. By becoming engineers, all fully trained on HMRC advertising, branding and digital services, a member of the Hub, organisations have legislation. and in Life Sciences we work in conjunction a single access point to dedicated facilities, Jumpstarts commitment to a premium with our partner Zyme Communications, networking, advice, events, promotion and proposition includes ISO 9001 Quality specialists in Life Sciences PR and marketing. funding opportunities. Accreditation, a significant contributor to our achievement of R&D Tax Advisory Firm of the kisscom.co.uk lifescienceshubwales.com Year. Simon Fryer, CEO Life Sciences Hub Wales [email protected] [email protected] Stand 44 029 2046 7030 jumpstartuk.co.uk Stand 11 Ross Leader, Client Engagement Manager [email protected] Stand 30

Since Eli Lilly and Company was founded MSP is the largest science and technology more than 135 years ago, our mission has park operator in the UK with 4 campuses remained unchanged: Create high-quality across the North West and provides over 1m medicines that make life better. Healthcare sq ft of specialist lab and workspace for life The London Bioscience Innovation Centre. challenges are complex and the unmet need science businesses. Owned by the prestigious Royal Veterinary is great; we know we can’t do it alone. We We provide the right environments for College (RVC), The London Bioscience must be innovative in our science and in our innovation to flourish and have been Innovation Centre is London’s premier approach to partnerships to bring medicines supporting the growth of companies in life incubator for life sciences, providing high to the people who need them. sciences and other sectors for 30 years. Our quality laboratory, office and technical OUR GREATEST INTERESTS INCLUDE: network of connections between innovators, support to over 60 companies. LBIC is located Oncology, Neuroscience, Diabetes, thinkers, investors and entrepreneurs brings next to the RVC and a short walk from St Immunology, Biotechnology, Emerging business and people together to transform Pancras International, Eurostar and the Markets, Drug Delivery and Devices, ideas into commercial reality and we Francis Crick Institute. Cardiovascular. We are passionate about accommodate businesses at every stage of The RVC provides a range of commercial engaging in innovative partnerships in any of their lifecycle – from start-ups to EU HQs and services via “RVC Business” for biomedical these areas. international centres of R&D excellence. companies looking to access technical and OUR APPROACH HAS THREE CRITICAL We are proud supporters of the Genesis academic expertise. Our contract research COMPONENTS: conference as a vital way to raise the profile unit covers routine animal husbandry and COMMUNICATE: Hear your ideas, Share our of the sector in the North West and provide laboratory services through to full study and interests, and Start the conversation a showcase for investment opportunities to design management within regulatory and EXPLORE: Dive into the science, strategy, and drive future growth. non-regulatory environments. commercial potential of every project MSP’s shareholders are Bruntwood Ltd, COLLABORATE: Integrate our collective The University of Manchester, Manchester strengths to shape the science to benefit Metropolitan University, Central Manchester patients. University Hospitals NHS Foundation Trust lbic.com and Manchester, Cheshire East and Salford Dr Ken Larkin, Chief Executive Kerri Lawford, Administrator, Search and City Councils. [email protected] Evaluation, Corporate Business Development 0207 691 1122 Stand 37 [email protected] Stand 9 +44 (0) 1276 483454 Stand 33 Create. Connect. Collaborate.

At Manchester Science Partnerships, Our network of connections between innovators, thinkers, investors and entrepreneurs brings business we provide the right environments and people together to transform ideas into commercial for innovation to flourish. Be a part of reality. We accommodate businesses at every stage of Manchester Science Partnerships to their lifecycle – from start-ups to HQs and international centres of R&D excellence. benefit from:

• Over 1m sq ft of lab and office space

• Open innovation campuses

• Collaborative workspaces and communities

MERESIDE CAMPUS – ALDERLEY PARK NEW DEVELOPMENT AT ALDERLEY PARK NO.1 MSP CENTRAL CAMPUS

To join our community of collaborators call 0161 279 6969 or email [email protected] Or to speak to us about new bio and life science lab and office opportunities at Alderley Park call Dr Chris Doherty, Site Director on 07770 640 757 or email [email protected] 40 exhibitors

Mathys & Squire is one of Europe’s top MedCity is bringing together the world- New Scientist Jobs is a dedicated job site for Intellectual Property firms. Since our leading strengths of the London-Oxford- science, technology, engineering and maths formation in 1910, we have been committed Cambridge golden triangle with four main helping you to attract relevant and qualified to building genuine partnerships with our priority areas: candidates. As part of the New Scientist clients. • Providing a single branded front door family, we can offer one essential platform for The biotechnology group at Mathys & for industry and investors, supported by a your recruitment messages online, in print Squire has an enviable record of success. connected concierge service and via social media. Our patent attorneys hold a wide range of • Knowing the market so the region’s offer scientific degrees, and many hold further fits with and supports global life sciences degrees and PhDs. Some attorneys have development worked within multinational corporations, • Fostering an environment that supports further enhancing our ability to maximise the and encourages entrepreneurialism value of our clients’ assets. Our commercial • Promoting the region globally as a world- understanding helps us advise clients, leading centre for life sciences research, ranging from spin-out stage to multi-million commercialisation and manufacturing pound funding projects, and has helped us to MedCity was established by Mayor of London secure innovative licensing deals. Boris Johnson with the capital’s three leading With offices in Cambridge, London, research and clinical institutions - Imperial Manchester, Reading and York, we are well- College Academic Health Science Centre, placed to meet with our UK-based clients King’s Health Partners, and UCL Partners – in face-to-face, to help get the best out of their April 2014. ideas. medcityhq.com Emily Buxton mathys-squire.com @MedCityHQ [email protected] Craig Titmus, Senior Associate [email protected] +44 (0)20 8652 4444 [email protected] Sarah Haywood, Chief Operating Officer Stand 38 Stand 41 Stand HS

Norwich Research Park is a vibrant Nova Language Services: specialist in Established in 1875, Page White & Farrer is community comprised of innovation led delivering workable solutions in translation. a leading UK firm of patent and trade mark companies, 4 world leading science research We are internationally recognised Life attorneys. Our comprehensive services institutes, the University of East Anglia and Sciences experts, with a global presence include assistance with invention capturing, the Norfolk & Norwich Hospital. The key and a well-established reputation. Our filing and obtaining patents in the UK, at the areas of focus are Med-Biotech, Food & services meet the quality standards required European Patent Office and worldwide. We Health, Industrial Biotech and Agritech. of even the most heavily regulated fields, conduct European patent oppositions, advise The Park provides a supportive environment such as clinical research and regulatory on freedom to operate, and provide due for innovation and growth. Services address affairs. We have in-depth knowledge of all diligence and portfolio services. We have a the needs of science based businesses and therapeutic areas and manage projects while wealth of experience working with individual include clinical trials facilities, biorepository, paying close attention to specific needs and inventors, academic/research institutions, shared laboratories, extensive genomics, requirements. All this with the level of care start-ups and other emerging entities. Our proteomics & metabolite services. Facilities and insight demanded by the most exacting specialist team of life science attorneys are include both formal and informal meeting of clients. experts in providing legal, practical and space, contemporary cafés, free wifi and Give us your words. We’ll turn them into strategic advice, translating your innovation ample parking. solutions. into valuable business assets. There is a range of cost effective accommodation options comprising offices and laboratories with flexible terms plus development land for further growth. pagewhite.com Less than 20 minutes’ drive from Norwich Stand 3 International Airport and only 1 hour from Cambridge, Norwich Research Park is currently home to over 40 businesses and nova-transnet.com 3,000 researchers and clinicians. Arun Mathew, Business Unit Director norwichresearchpark.com [email protected] Kenny Lang, Business Development Director Stand 43 [email protected] +44 (0) 1603 673 671 Stand 13 exhibitors 41

Red: PMS 185 C CMYK: 0.92.76.0 RGB: 224.0.52 HTML: E00034

Founded in 2002, Pharmidex is a CRO For 35 years, QuickSTAT has managed clinical Grey: PMS 431 C Pharma Publications is a dynamic media CMYK: 4 5.27.17.51 with extensive CNS drug discovery and trial logistics in more than150 countries RGB: 94.10 6.113 organisation, specialising in publications for HTML: 5E6A71 the Life Sciences Industry. With a portfolio ADMET/PK expertise. Pharmidex provides worldwide. With innovative solutions that of publications like, IPI (International tailored studies critical to the progression of offer complete end-to-end transportation services, your time and temperature-sensitive Tagline font: Pharmaceutical Industry), JCS (Journal for drug discovery programmes and research Univers 57 Condensed Oblique Clinical Studies), JPC (Journal for Patient collaborations. Pharmidex has been able to clinical research specimens, investigational Compliance) and IAHJ (International deliver a high level of customer satisfaction drugs, and biologics are handled with Animal Health Industry) we inform the and forge several strategic international unmatched attention, reliability and care. Pharmaceutical Industry on the best practice alliances, focussing on operations in in outsourcing management. Providing the following areas: in vitro ADMET, peer reviewed articles and analysis on Pharmacokinetics, Pharmacology, CNS drug discovery, drug development, clinical Drug Discovery, Bioanalysis, Metabolite research, manufacturing, packaging, supply Identification, and Toxicology. Pharmidex chain management, patient adherence and clients include Pharma, biotechs, health outcomes, we provide comprehensive governmental institutes, universities and guidelines to help the industry grow. We are medical charities. Pharmidex has also your one-stop-shop for all your marketing to extensive experience in grant funded the pharmaceutical industry. collaborations with numerous successful ongoing and completed projects. ipimediaworld.com, jforcs.com, jforpc.com, animalhealthmedia.com pharmidex.co.uk Stand 39 Orsolya Balogh - Editor quickstat.aero [email protected] [email protected] Stand 40 Stand 45

RGCC Pharma is one of the members of the Scottish Development International is SCRIP is a leading source of news RGCC group, is located in Bristol, UK, and the economic development agency for and strategic analysis for the global holds all the rights of the new developed Scotland and is a joint venture between the pharmaceutical industry. We filter the flood pharmacophore agents and candidate drugs. Scottish Government, Scottish Enterprise and of information on the industry and apply The company, in collaboration with the other Highlands & Islands Enterprise. the knowledge of our extensive network of members of the group, analyses multiple Since it was founded 11 years ago, SDI has analysts, journalists and key opinion leaders biological samples, identifies repeatable transformed Scotland’s economic outlook, to provide our readers with timely business patterns of proteins that may be related with attracting some of the world’s biggest critical market and competitor intelligence. the disease development and validates them. companies to locate in the country, growing According to the location of the drugable Scottish exports and creating over 19,000 target the company will proceed to develop new jobs. either of a monoclonal antibody or a small Scotland hosts one of the largest life molecular weight organic molecule with science clusters in Europe with significant inhibitory properties. So far the pipeline international presence in research, includes agents related to stemness as well development and manufacturing. With a as cancer cell metastases. long and remarkable history of medical and scientific discovery stretching back 200 years, Scotland has always been at the forefront of medical innovation. [email protected] Dr. Roger Oakes 0044 (0) 1179058738, 0044 (0) 1172305034 Stand 4 sdi.co.uk scripintelligence.com Fiona Jefferson, International Senior Stand 32 Executive [email protected] Stand 20 42 exhibitors

Sequani is a preclinical CRO based in Sidley Austin LLP is a premier law firm. Our Stockholm-Uppsala is the country’s largest Ledbury (UK) that has an international global team provides strategic legal advice to life science region, where business and reputation for excellence in the field of businesses in the biotech sector, representing research thrive. Our region is a hot-bed of toxicology. Established for over 40 years, local clients in the UK, as well as international creative cross-disciplinary collaboration with key areas of expertise such as First- corporations and investors across Europe, the and together, we build international in-Man (Phase I) enabling programmes, U.S. and Asia. businesses and deliver real research Reproduction Toxicology and Juvenile breakthroughs that help solve some of Toxicology, across many therapeutic the world’s health problems. We are open- indications and to support each stage of minded and productive. Our state-of-the-art clinical drug development. infrastructure and talented scientists provide all the services and support you will need. Being a small/medium-sized facility of Our companies are global from day one. approximately 180 people, we take a flexible and creative approach to drug development, Meet some of our companies represented working closely with our customers to design at Genesis during breaks, at one-to-one bespoke, tailored pre-clinical programmes to meetings or in our booth. Or come by and meet their specific clinical objectives. talk to us about the assets of our region. We are happy to show our potential for business, collaboration and investments.

sequani.com sidley.com suls.se Stand 12 Mark Thompson, Partner Ywonne Bölja, Marketing Director [email protected] [email protected] +44 20 7360 3730 Stand 15 Stand 17

Syne qua non (SQN) is one of the largest TranScrip is a trusted partner in providing UK Trade & Investment (UKTI) is the UK’s functional Biometrics CROs in Europe strategic leadership and operational international trade and inward investment providing global pharma, biotech, capacity for over 100 companies across five promotion organisation. We provide support medical device and animal health continents. Our range of clients includes and assistance to new and existing UK partners with innovative, cost effective both biopharma SMEs and 20 of the top 50 exporters of goods and services, and our development services in eCRF/CRF design, pharma. network reaches over 100 markets overseas data management, statistics, EDC trial TranScrip supports the development and supporting businesses locally. We also lead management, ePRO, project management, lifecycle management of biopharmaceutical an inward investment network including quality management, consultancy and products. We provide expertise, resourcing private sector expertise to help overseas- audits and medical writing. Our powerful, and strategic oversight from translational owned firms locate and build their business yet flexible, site-friendly EDC system can be medicine to successful registration and in and from the UK. UKTI’s Life Sciences rapidly developed delivering high quality market access. Organisation (LSO) catalyses and coordinates data with real-time, drilldown reporting Our range of services includes facilitating life sciences trade and inward investment within a competitive pricing model. Working selection/progression of preclinical drug across the whole of the UK. as if part of your team our can-do culture candidates through to POC, support for provides a service that is refreshingly partnering exercises and throughout clinical different from other CROs. development and registration. In summary, our talented, insightful teams Tony Rees, Director help you maximise your opportunities, [email protected] reduce risk and create value. Tel: +44 (0) 1379 644449 www.synequanon.com Stand 42 transcrip-partners.com gov.uk/ukti/lso Stand 1 @UKTI_LSO Stand 10 exhibitors 43

United Life Sciences is a strategic UMIP® is The University of Manchester’s United offers unrivalled access to the partnership representing over 1,000 life agent for intellectual property U.S. with nonstop flights from seven U.K. science and healthcare organisations commercialisation. UMIP’s three operational airports, and onward connections to over across the UK and internationally. The ULS teams: Scouting; IP Development and 300 destinations across the Americas. With collaboration has member and the wider UK Partnering; and Enterprise and Business services from London Heathrow, Manchester, life science sector benefit at the heart of its Development are responsible for identifying, Birmingham, Edinburgh, Glasgow, Belfast purpose and is the basis for all joint activities. protecting and commercialising the and Newcastle, United offers nonstop It strives to avoid duplication of effort and University’s IP. UMIC® is the University’s transatlantic flights from more U.K. cities than coordinates the five organisations’ activities Innovation Centre-its bioscience incubators any other airline. And you won’t just arrive: whilst recognising each other’s areas of include the successful Manchester Bioscience you’ll arrive refreshed, thanks to our superior strength so that member companies can Incubator and the Core Technology Facility levels of comfort and personal service. From benefit from more effective and coherent (CTF). UMIC® also provides conferencing and extra legroom in United Economy Plus® to sector support. meeting room facilities. UMIP® and UMIC® 180 degree flat-beds in United BusinessFirst®, are divisions of The University of Manchester air travel is a pleasure. One Nucleus - Harriet Fear, [email protected] Innovation Group Ltd; www.umi3.com

BIA – Steve Bates, [email protected]

Bionow - Geoff Davison, geoff.davison@bionow. co.uk

BioPartner - Lin Bateson, [email protected] umip.com United.com MediWales - Debbie Laubach, debbie.laubach@ [email protected] David Davis, Corporate Account Manager mediwales.com umic.co.uk [email protected] Stand 49 [email protected] BioCafe Stand 22

World Courier is a global specialty logistics Zyme Communications Ltd provides company that designs world-class strategic and specialist communications logistics and supply chain programs in services for the life science sector. Based in complete alignment with our customers’ Cambridge and Manchester in the UK, and business goals. Pharmaceutical companies with clients across Europe and the USA, rely on us because they value the Zyme is focused on supporting companies to peace of mind that comes with our raise their profile and generate interest from unsurpassed knowledge, global reach and commercial leads, investors and partners. flawless supply chain execution. Each trusted With an international network of life science partnership we form with a customer trade media contacts and a strong technical is deeply rooted in our shared vision of understanding, Zyme is committed to improving global health. With 2,000+ delivering value and results from objective- associates in more than 140 offices across the lead communications. globe, we offer solutions that instill confidence in the on-time, on-temperature delivery of critical products. When trust zymecommunications.com is absolutely essential, there’s only one Lorna Cuddon, Managing Director choice: World Courier. [email protected] +44 (0)1223 968 920 Stand 29

worldcourier.com Stand 26 Life Sciences Hub Wales is the nerve centre of a vibrant and prosperous Welsh Life Sciences eco-system, it brings together academic, business, clinical, professional services, government and funding organisations to provide a commercially-driven melting pot of talent.

Designed to facilitate innovation and growth, the Hub hosts and engages Life Sciences Go organisations large and small. Member organisations and partners have a single access point to dedicated facilities, further, co-ordinated support, networking, advice, events, promotion and funding faster opportunities. Meet the team Stand 11 Enterprise Europe Network Tel: +44 (0)29 2046 7030 London Email: [email protected] The route lifescienceshubwales.com to new markets new funding new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 Life Sciences Hub Wales is the nerve centre of a vibrant and prosperous Welsh Life Sciences eco-system, it brings together academic, business, clinical, professional services, government and funding organisations to provide a commercially-driven melting pot of talent.

Designed to facilitate innovation and growth, the Hub hosts and engages Life Sciences Go organisations large and small. Member organisations and partners have a single access point to dedicated facilities, further, co-ordinated support, networking, advice, events, promotion and funding faster opportunities. Meet the team Stand 11 Enterprise Europe Network Tel: +44 (0)29 2046 7030 London Email: [email protected] The route lifescienceshubwales.com to new markets new funding new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 INNOVATIVE SOLUTIONS FOR THE BIOTECH LANDSCAPE 28 June 2016 Cambridge, UK Sidley is a leader in advising biotech innovators and investors throughout the lifecycle of their products and investments. Working seamlessly with the ﬁ rm’s lawyers across the United States, Europe and Asia, we help clients navigate the range of issues inherent in the industry—from the science and technology opportunities to the legal and business challenges.

TALENT. TEAMWORK. RESULTS.

Scott Bass Partner [email protected] +1 212 839 5613 +1 202 736 8684

Coleen Klasmeier RECOGNIZED AS Partner A LEADING LAW FIRM [email protected] IN PHARMACEUTICALS +1 202 736 8132 AND BIOTECHNOLOGY Maarten Meulenbelt Translating UK scientific Partner – THE LEGAL 500 [email protected] excellence into global UNITED KINGDOM 2015 +32 2 504 6467

Mark Thompson therapeutic strategies Partner [email protected] +44 20 7360 3730

sidley.com

AMERICA • ASIA PACIFIC • EUROPE

Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212 839 5300; One South Dearborn, Chicago, IL 60603, 312 853 7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202 736 8000. Sidley Austin refers to Sidley Austin LLP and afﬁ liated partnerships as explained at www.sidley.com/disclaimer. Prior results do not guarantee onhelix.com Our translational research conference a similar outcome. MN-2799 28 June 2016 Cambridge, UK

Translating UK scientific excellence into global therapeutic strategies

onhelix.com Our translational research conference 20151002_EMEAI_BusinessFirstMagazine2 copy.pdf 1 02/10/15 12:47

CMY